Monte Rosa Therapeutics Presents Preclinical Data At EULAR 2024 Regarding MRT-6160 For Treatment Of Rheumatoid Arthritis

Benzinga · Jun 14 20:46

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis

Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Monte Rosa Therapeutics Presents Preclinical Data At EULAR 2024 Regarding MRT-6160 For Treatment Of Rheumatoid Arthritis

Risk Disclaimer